Pfizer's COVID-19 Booster Shot yana da tasiri ga Aƙalla watanni 9-10: Nazari
Pfizer's COVID-19 Booster Shot yana da tasiri ga Aƙalla watanni 9-10: Nazari
Anonim

Har yanzu akwai wannan ma'anar rashin tabbas idan aka zo ga yanayin COVID-19 gaba ɗaya yayin da ƙasashe da yawa ke ba da rahoton ƙarin kararraki yayin da wasu ke lura da raguwar watsawa. A cikin bala'in cutar, da yawa suna juya harbin ƙararrawa azaman hanya don samar da ingantacciyar kariya daga SARS-CoV-2. Kuma ya zuwa yanzu, akwai kwararan shaidun da ke nuna cewa ƙarin allurai na iya yin babban bambanci a cikin barkewar cutar.

Tasirin Shots Booster

Pfizer shine kamfani na farko na harhada magunguna da aka ba da izinin fitar da allurar rigakafin cutar ta COVID-19. Dangane da bayanan farko daga binciken Isra'ila, kashi na uku ba wai kawai yana samar da ƙarin ƙwayoyin rigakafi ba, yana kuma samar da ƙwayoyin rigakafi waɗanda ke da kyau idan ana batun hana kamuwa da cuta.

Masu bincike a asibitin Tel Hashomer sun gano cewa kwayoyin rigakafin da aka samar da allurar kara kuzari na iya samar da ingantacciyar kariya idan aka kwatanta da allurai biyu na farko na rigakafin. Bugu da kari, an kuma gano cewa harbin na kara kuzari yana da tasiri na akalla watanni 9-10 ko ma fiye da haka, in ji The Times of Israel.

Don binciken wanda Makarantar Kiwon Lafiya ta Harvard ta ba da tallafi kuma Babban Babban HMO Clalit Health Services na Isra'ila ya gudanar, masu bincike sun bincika bayanai daga mutane 728, 321 waɗanda suka karɓi jabs mai ƙarfafawa kuma sun kwatanta shi da bayanan ƙungiyar kulawa na adadin mutanen da suka yi kama da su. kawai an sami alluran rigakafin biyu na farko.

"Sakamakon ya nuna ta hanya mai gamsarwa cewa kashi na uku na rigakafin yana da matukar inganci," in ji babban jami'in kirkire-kirkire na Clalit Ran Balicer.

COVID-19 Mai Rarraba Alurar rigakafi

Hukumar Abinci da Magunguna (FDA) a hukumance ta ba da izinin amfani da Pfizer-BioNTech's COVID-19 mai haɓaka rigakafin rigakafi a cikin Satumba. A yayin kaddamar da aikinta na farko, hukumar ta tarayya ta nuna cewa ya kamata a baiwa mutane masu shekaru 65 da haihuwa fifiko, tare da mutane masu shekaru 18 zuwa 64 da ke da yanayin da ke jefa su cikin hatsarin kamuwa da cuta mai tsanani. FDA ta kuma lissafa yawan jama'a waɗanda aka ƙarfafa su sosai don samun abubuwan haɓakawa nan take.

"Bayan la'akari da jimillar shaidar kimiyya da kuma shawarwarin kwamitinmu na ba da shawara na masu zaman kansu, ƙwararrun masana na waje, FDA ta gyara EUA don rigakafin Pfizer-BioNTech COVID-19 don ba da damar ƙara ƙarin kashi a wasu al'ummomi kamar kiwon lafiya. ma'aikata, malamai da ma'aikatan kula da rana, ma'aikatan abinci da waɗanda ke cikin matsuguni ko gidajen yari, da sauransu, "in ji Kwamishinan FDA Janet Woodcock, MD.

A cikin Oktoba, FDA ta kuma ba da izinin yin amfani da masu haɓakawa don rigakafin Moderna da Johnson & Johnson. Hukumar ta kuma ba da sanarwar a lokacin cewa ba za a bukaci mutane su sami karin adadin da ya yi daidai da jerin alluran rigakafin su na farko ba, wanda ke bude kofofin hadawa da daidaita nau'ikan rigakafin, kamar yadda STAT ta nuna.

Cibiyar Kula da Cututtuka da Cututtuka (CDC) tun daga lokacin ta ba da jagorar da ke nuna kwarin gwiwa iri ɗaya don haɗawa da daidaita samfuran allurar rigakafi da masu haɓakawa. A cewar hukumar kula da lafiyar jama'a, Pfizer, Moderna da Janssen masu karɓar alluran rigakafin an ba su damar samun ƙarin allurai daga kowane nau'ikan samfuran ukun da aka ba da izini. Koyaya, CDC ta yi nuni da cewa wasu masu karɓar J&J na iya fifita mai haɓakawa daga sauran samfuran biyu saboda maganin Janssen yana da ƙarancin tasiri idan aka kwatanta da allurar mRNA.

Shahararren taken